India rejects GILD’s Sovaldi patent, but it probably doesn’t matter much insofar as GILD previously licensed Sovaldi to various Indian generic-drug companies for a paltry royalty on sales (#msg-105023468):
The patent decision shows that India still has a long way to go in protecting foreign companies' drug/biotech IP. This is why I was careful to say that the decision in #msg-109867353 did not constitute a trend.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.